267 results about "AIDS diagnosis" patented technology

The invention relates to the field of disease prediction, in particular to an epilepsy prediction system based on synchronously acquired electroencephalogram-gastric electrical signals, comprising: a data acquisition module for acquiring data including electroencephalogram data and gastrointestinal electrical data; the first analysis module is used for obtaining an average electrode inconsistency index of the first channel and the second channel based on a first model according to the time sequence data; and the prediction module is used for comparing the average electrode inconsistency index of the subject with a preset evaluation threshold value so as to predict an epileptic. The system provided by the invention can more accurately and efficiently distinguish epilepsy patients from healthy people, and can be used as an auxiliary diagnosis tool to be applied to primary screening of epilepsy of relatively large people (such as communities and physical examination centers).

The invention relates to the technical field of medical clinical auxiliary diagnosis, in particular to an orthopedic postoperative complication early detection and early warning system based on data analysis, which comprises a multi-modal sign synchronous acquisition module, a sign dynamic difference quantification module, a complication feature association module, a grading early warning decision module and a dissection calibration visualization module. Wherein the multi-modal sign synchronous acquisition module is used for acquiring postoperative data of a patient; calculating a difference quantization parameter; the complication characteristic association module is used for identifying associated risk characteristics of the osteofascia ventricular syndrome, the deep venous thrombosis and the fat embolism; and the grading early warning decision module is used for generating a three-level early warning instruction based on the associated risk characteristics. According to the system and the method, through a multi-modal sign synchronous acquisition, difference quantification and grading early warning linkage mechanism, accurate recognition, risk grade division and visual intervention guidance of postoperative complications are realized, and the continuity of postoperative monitoring and the timeliness of early warning are improved.

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to a kit for breast cancer diagnosis and application thereof. The kit comprises an elisa plate coated with a captured antibody and an HRP labeled antibody working solution, the capture antibody is a monoclonal antibody T2X-1 of an anti-PSTPIP1 protein; the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an anti-PSTPIP1 protein, and the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an The heavy chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.1, and the light chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.2; the heavy chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.4. The kit for breast cancer diagnosis provided by the invention can be used as an auxiliary diagnosis means for breast cancer with high expression of PSTPIP1 protein, and has high diagnostic value.

The invention discloses a recombinant protein and a detection reagent for detecting encephalitis of an anti-GABABR antibody, and belongs to the technical field of neuroimmunology diagnos.A GABABR1 partial sequence, a GABABR2 partial sequence and a transmembrane sequence (and a fluorescent label) are adopted to construct a cell strain for stably and highly expressing the recombinant protein by transfecting CHO cells or HEK293 cells, and the recombinant protein and the detection reagent are used for detecting the encephalitis of the anti-GABABR antibody. The sensitivity and the specificity of the kit in anti-GABABR antibody encephalitis detection can be remarkably improved, the aim of detecting the antibody by using a fixed CBA method or a living cell CBA method can be achieved, and the kit is suitable for auxiliary diagnosis of autoimmune encephalitis of cerebrospinal fluid / serum.

The invention discloses a mental disease medical auxiliary diagnosis method based on a bimodal knowledge graph and a related device, and relates to the technical field of mental disease diagnos.The method comprises the steps that a static medical diagnosis knowledge graph is constructed; generating a scenarized problem library based on the static medical diagnosis knowledge graph; dynamically updating a personal dynamic knowledge graph based on interaction between the scenarized question library and a user; and finally, optimizing the static medical diagnosis knowledge graph based on the personal dynamic knowledge graph. According to the invention, through cooperation of the static and dynamic knowledge maps, objectivity, dynamics and accuracy of mental disease diagnosis are improved, and closed-loop management of medical auxiliary diagnosis is realized.

The invention provides an intelligent diagnosis and treatment method and system for teenager depression based on large model collaboration, and the method comprises the steps: constructing a remote sensing human living microenvironment and growth soft environment data set, carrying out the preprocessing and feature extraction of the data set, carrying out the space-time matching and characterization of the environment and the brain-behavior clinical data of a subject individual, and carrying out the diagnosis and treatment of the teenager depression. Individual intervention queue data and feature representation matched with the environment are collected; establishing a knowledge graph based on a large model based on the acquired multi-dimensional data; and performing intelligent diagnosis and intervention of environment-brain-behavior enhancement based on the established knowledge graph. Based on a knowledge organization system of environment-brain-behavior auxiliary diagnosis, pathogenesis evaluation and individualized intervention, an environment-brain-behavior multi-dimensional knowledge graph oriented to adolescent depression diagnosis is constructed, and based on a large-model collaborative reasoning mechanism enhanced by environment-brain-behavior multi-dimensional knowledge, the adolescent depression diagnosis is more accurate. An intelligent and precise method system is provided for diagnosis and treatment of juvenile depression, and the diagnosis and treatment level is greatly improved.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention relates to the technical field of tumor markers, in particular to a pancreatic cancer early screening marker combination based on blood protein and application of the pancreatic cancer early screening marker combination. Through proteomics analysis and bioinformatics screening, 12 kinds of proteins such as NME3, HPGDS, CEACAM5, TNFSF12, SCG3, VTCN1, GFRA1, KRT19, TMPRSS12, NELL2, KAZALD and MMP12 are determined to serve as the potential early screening markers of the pancreatic cancer. Researches show that the combination of the proteins can effectively distinguish pancreatic cancer patients from non-pancreatic cancer patients, and has good sensitivity and specificity. A screening model constructed based on the protein combination can be applied to auxiliary diagnosis, risk assessment and population screening of pancreatic cancer, and has important clinical transformation value.

The invention relates to the technical field of medical detection, in particular to application of a TTR tetramer in preparation of a product for diagnosing ejection fraction retention type heart failure. Experiments prove that in heart failure patients, TTR tetramers in HFpEF patients are obviously higher than those in non-HFpEF patients, and it is prompted that the TTR tetramers are related to HFpEF. According to the present invention, the diagnosis model and the kit using the TTR tetramer as the biomarker have good sensitivity and good specificity, can achieve the diagnosis or the auxiliary diagnosis, the treatment guidance and the prognosis of the HFpEF, and can improve the identification of different heart failure types such as the HFpEF and the non-HFpEF.

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention relates to the technical field of medical diagnosis, and provides a multi-modal dementia analysis auxiliary diagnosis method, system and device, a medium and equipment, and the method comprises the steps: obtaining an inquiry video of a patient, and carrying out the multi-modal feature extraction of the video, and obtaining a multi-modal feature data set; analyzing the voice feature data based on a large language model and a preset voice standard to obtain voice dimension information; analyzing the text feature data based on a large language model and a preset text standard to obtain text dimension information; analyzing the visual feature data based on a large language model and a preset visual standard to obtain visual dimension information; performing time alignment processing and feature fusion processing on the modal feature data to obtain a comprehensive multi-modal feature vector; and carrying out dementia symptom diagnosis analysis based on the large language model and a pre-constructed clinical dementia rating scale, and determining a diagnosis result based on an analysis result and the modal dimension information. The accuracy and efficiency of dementia diagnosis can be improved.

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

The invention relates to a multi-mode ophthalmology auxiliary diagnosis and nursing follow-up visit system which comprises a multi-mode ophthalmology basic data collection module used for obtaining a patient identifier when a patient inquires for the first time, obtaining new multi-mode ophthalmology basic data of the patient in each disease course stage according to the patient identifier, and sending the new multi-mode ophthalmology basic data to a follow-up visit module; determining auxiliary information of the new multi-mode ophthalmology basic data, and storing the new multi-mode ophthalmology basic data and the auxiliary information; the whole-course auxiliary diagnosis module is used for determining an auxiliary diagnosis decision according to the multi-mode ophthalmology basic data and the auxiliary information; the whole-course nursing follow-up visit module is used for determining a follow-up visit level and generating a nursing follow-up visit scheme according to the multi-mode ophthalmology basic data and auxiliary information; and the output module is used for outputting a nursing follow-up scheme and / or an auxiliary diagnosis decision according to the follow-up level, so that the auxiliary diagnosis nursing follow-up of the whole disease course stage can be realized, and the auxiliary accuracy of each disease course stage is ensured.

The present invention discloses a biomarker for assisting in the diagnosis of bone metastasis of lung adenocarcinoma. The present invention specifically provides an application of a biomarker or a detection reagent thereof in the preparation of a product for assisting in the diagnosis or early screening of bone metastasis of lung adenocarcinoma, wherein the biomarker is AA and / or ANGPTL4. The present invention applies AA and / or ANGPTL4 to the diagnosis of bone metastasis of lung adenocarcinoma for the first time, and provides a simple, non-invasive, and long-term available detection method through serum testing; compared with the existing technology, the present invention can achieve earlier diagnosis of bone metastasis, and avoids the health risks brought by radiation, and has a high clinical application value; in short, the present invention provides a new biomarker combination for the early diagnosis of bone metastasis of lung adenocarcinoma, which is expected to provide more accurate guidance for the clinical treatment of patients, and is of great significance for the long-term monitoring of tumor metastasis.

To provide a new method, model, program or the like for acquiring information usable for a disease diagnosis or prognosis prediction by using a sample taken from lungs or exhaled breath.SOLUTION: A method for assisting disease diagnosis or prognosis prediction including: acquiring (A) extracellular particle information on a population of extracellular particles collected from lungs or exhaled breath of a subject; the extracellular particle information including scattered light information on scattered light of irradiated light about each extracellular particle of the population of extracellular particles, and light emission information on a plurality of light emission whose peak wavelengths are mutually different, caused from a component of the extracellular particles or a labelling substance connected to the component due to the irradiated light; and (B) disease information on a state of a disease in the subject from each subject included in a group of subjects; and acquiring information for assisting the disease diagnosis or the prognosis prediction related to the extracellular particles collected from the lungs or the exhaled breath by machine learning on the basis of a data set including the extracellular particle information and the disease information.SELECTED DRAWING: Figure 1

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

This invention discloses an anti-HIV antibody or a functional fragment thereof and its applications. The anti-HIV antibody or functional fragment disclosed in this invention includes a heavy chain complementarity-determining region and a light chain complementarity-determining region. This antibody or functional fragment has good specificity and sensitivity for HIV and can be used to detect human immunodeficiency virus (HIV) and for the diagnosis or auxiliary diagnosis of related diseases using HIV as a biomarker.

The application relates to the field of biological medicine, discloses application of a biomarker in an in-vitro auxiliary diagnosis product of sepsis complicated with ARDS, the biomarker is PDLIM1 in peripheral blood; further includes a detection kit and a use method thereof. The application first proposes that the PDLIM1 protein can be used as a biomarker to detect sepsis complicated with ARDS, compared with detection by means of a "combined judgment" method, the detection product can help medical staff to perform rapid detection, and in a ROC curve diagram, the AUC of PDLIM1 is greater than 0.8, the detection result is reliable, and the operation mode is relatively simple, so that the detection time is compressed, and the medical starting time is reduced.

The invention belongs to the technical field of biological medicine, and particularly relates to application of GLUT5 serving as a colorectal cancer biomarker in development of an in-vitro detection kit, a prognosis model and an inhibitor. The GLUT5 is highly expressed in colorectal cancer tumor-related fibroblasts (CAFs), the expression level of the GLUT5 is remarkably related to poor prognosis of a patient, and the GLUT5 can be used as a molecular basis for auxiliary diagnosis and an independent prognosis factor. In mechanism, the GLUT5 promotes tumor progression by mediating fructose metabolism reprogramming of the CAFs. A full-chain solution from early diagnosis and precise prognosis to targeted therapy is provided for colorectal cancer, and the clinical transformation value is remarkable.

The application relates to the field of disease prediction, and particularly relates to an epilepsy prediction system based on electroencephalogram-electrogastrogram signals collected synchronously, which comprises the following modules: a data acquisition module, which is used for acquiring data, wherein the data comprises electroencephalogram data and electrogastrogram data; a first analysis module, which is used for obtaining average electrode inconsistency indexes of first channels and second channels based on a first model according to time sequence data; and a prediction module, which is used for comparing the average electrode inconsistency indexes of a subject with preset evaluation thresholds, so as to predict epilepsy patients. The system provided by the application can more accurately and efficiently distinguish epilepsy patients from healthy people, and can be applied to the preliminary screening of epilepsy for a large population (for example, a community or a physical examination center) as an auxiliary diagnosis tool.

The invention discloses a human papilloma virus mRNA (messenger ribonucleic acid) detection kit for auxiliary diagnosis of cervical cancer patients. The human papilloma virus mRNA detection kit comprises a nucleic acid probe group and a series of nucleic acid probes AMP1-AMP5, wherein the nucleic acid probe group is used for being combined with a human papilloma virus mRNA target, and the nucleic acid probes AMP1-AMP5 are used for signal amplification. The human papilloma virus mRNA detection kit provided by the invention can assist pathologists in identifying and diagnosing cervical cancer patients, and provides a basis for clinicians to formulate a therapeutic schedule.

The utility model discloses a portable traditional Chinese medicine olfactory diagnosis instrument, which comprises a sample collection device, a gas enrichment device, a mass spectrometer, a data processor and a display, the mass spectrometer is sequentially connected with the data processor and the display, the gas enrichment device is test paper with an enrichment reagent encapsulating nano-metal particles, the enrichment efficiency is effectively improved, and the detection accuracy is improved. Therefore, the detection sensitivity and accuracy of the mass spectrometer are improved; the device is provided with the ion trap mass spectrometer, has the characteristics of high detection speed, high resolution and high sensitivity, and has performance advantages in qualitative and trace analysis aspects; and due to small volume and strong portability, the device can be conveniently integrated into portable or field detection equipment, can be used for auxiliary diagnosis of heart failure and asthma, and also has great clinical application value in the aspects of disease evolution and disease prognosis evaluation.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The invention discloses an interpretable machine learning method for predicting multi-organ injuries of diquat poisoning patients, and the method comprises the steps: constructing and verifying a prediction system of eight kinds of organ injuries through a clinical database; toxic encephalopathy, myocardial injury, acute kidney injury, circulatory failure, skeletal muscle injury, liver injury, lung injury and gastrointestinal tract injury are covered. According to the method, early-stage efficient prediction of multi-organ injury is achieved, deep insight is provided for potential biological mechanisms of organ injury, clinical formulation of individualized intervention strategies is facilitated, the prognosis management level of diquat poisoning patients is expected to be remarkably improved, and the incidence rate and case fatality rate of multi-organ failure are reduced. According to the technical scheme, high prediction precision is kept, meanwhile, balance of interpretability, stability and clinical applicability of the model is achieved, a reliable auxiliary diagnosis tool is provided for organ injury risk assessment of acute poisoning patients, and the method has important clinical application value and wide market prospects.

The application discloses a cervical cancer methylation detection kit and application thereof, the kit takes PAX5 gene, PAX1 gene, MICOS10-NBL1 gene and MICOS10 gene as detection targets; the kit mainly comprises specific primer probe dry powder combination, PCR reaction reagent dry powder, positive control product dry powder, negative control product dry powder and microdroplet generation oil. The sample is detected by bisulfite conversion, and the kit is combined with microdroplet digital PCR detection technology to realize accurate detection of the methylation level of the target gene. The detection verification result shows that the sensitivity of the kit for cervical cancer detection reaches 96.9%, the specificity reaches 95.7%, the kit has the advantages of accurate detection, simple operation and strong stability, can be widely applied to early screening, clinical auxiliary diagnosis and physical examination of healthy people of cervical cancer, and provides reliable technical support for early discovery and early treatment of cervical cancer.

The invention discloses a MAGE A1 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the MAGE A1 recombinant antigen disclosed by the invention is as shown in SEQ ID NO. 1. Through verification, compared with a full-length MAGE A1 antigen, the MAGE A1 recombinant antigen disclosed by the invention has the advantage that the sensitivity of the MAGE A1 recombinant antigen in early lung cancer detection is improved. Therefore, the MAGE A1 recombinant antigen provides a new way for early auxiliary diagnosis of lung cancer.